ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com



Ò½ÏßÒ©ÎÅ1. 9ÔÂ17ÈÕ£¬£¬£¬£¬£¬£¬¸´ºêººÁØÐû²¼£¬£¬£¬£¬£¬£¬Á¢ÒìÐÍCDK4/6ÒÖÖÆ¼ÁèÛéÚËá·üάÎ÷Àû½ºÄÒÐÂÔö˳Ӧ֢µÄÒ©Æ·×¢²áÉêÇë»ñµÃÖйú¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨NMPA) Åú×¼¡£¡£¡£±¾´Î»ñÅú˳Ӧ֢ΪÓÃÓÚ¼¤ËØÊÜÌ壨HR£©ÑôÐÔ¡¢ÈË±íÆ¤Éú³¤Òò×ÓÊÜÌå2£¨HER2£©ÒõÐÔ£¨HR+/HER2-£©¾Ö²¿ÍíÆÚ»ò×ªÒÆÐÔÈéÏÙ°©³ÉÈË»¼ÕߣºÓë·¼Ï㻯øÒÖÖÆ¼ÁÁªºÏʹÓÃ×÷Ϊ³õʼÄÚÉøÍ¸ÖÎÁÆ¡£¡£¡£
2. 9ÔÂ17ÈÕ£¬£¬£¬£¬£¬£¬»ªº£Ò©ÒµÍ¨¸æ£¬£¬£¬£¬£¬£¬¹«Ë¾ÏÂÊô×Ó¹«Ë¾»ª°ÂÌ©»ñµÃÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú×¼£¬£¬£¬£¬£¬£¬ÔÚÃÀ¹ú¿ªÕ¹×¢ÉäÓÃHB0043IÆÚÁÙ´²ÊÔÑé¡£¡£¡£¸ÃҩƷ˳Ӧ֢Ϊ»¯Å§ÐÔº¹ÏÙÑס£¡£¡£
3. 9ÔÂ17ÈÕ£¬£¬£¬£¬£¬£¬ÖÇ·ÉÉúÎïÐû²¼Í¨¸æ£¬£¬£¬£¬£¬£¬¿ËÈÕÓɿعÉ×Ó¹«Ë¾ÖØÇìå·°²ÉúÎïÖÆÒ©ÓÐÏÞ¹«Ë¾Ñз¢µÄCA111×¢ÉäÒº»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÒ©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊ飬£¬£¬£¬£¬£¬ÔÞ³ÉÔÚ³ÉÈ˳¬ÖØ»ò·ÊÅÖ»¼ÕßÖпªÕ¹ÁÙ´²ÊÔÑé¡£¡£¡£CA111×¢ÉäÒºÊÇÒ»¿îÆÏÌÑÌÇÒÀÀµÐÔÒȵºËØÊÍ·ÅëÄ£¨Glucose-dependent insulinotropic polypeptide£¬£¬£¬£¬£¬£¬GIP£©ÊÜÌåºÍÒȸßѪÌÇËØÑùëÄ-1£¨Glucagon like peptide-1£¬£¬£¬£¬£¬£¬GLP-1£©ÊÜÌåµÄË«ÖØ¼¤¶¯¼Á¡£¡£¡£
4. ¿ËÈÕ£¬£¬£¬£¬£¬£¬¿µ³¼Ò©ÒµÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄ¶÷¸ñÁо»Æ¬»¯Ñ§Ò©Æ·4Àà×¢²áÖ¤Ê飨¹úÒ©×¼×ÖH20255356£©£¬£¬£¬£¬£¬£¬ÊÓͬͨ¹ý·ÂÖÆÒ©ÖÊÁ¿ºÍÁÆÐ§Ò»ÖÂÐÔÆÀ¼Û¡£¡£¡£Õâ±ê¼Ç×Å¿µ³¼Ò©ÒµÔÚÉö²¡ÖÎÁÆÁìÓòÔÙÌíгÉÔ±£¬£¬£¬£¬£¬£¬Îª¹«Ë¾Î´À´Òµ¼¨Ò»Á¬ÔöÌí×¢ÈëÇ¿¾¢¶¯Á¦¡£¡£¡£
1. 9ÔÂ17ÈÕ£¬£¬£¬£¬£¬£¬Ollin BiosciencesÐû²¼Íê³É1ÒÚÃÀÔªÈÚ×Ê£¬£¬£¬£¬£¬£¬Í¶×Ê»ú¹¹°üÀ¨ARCH Venture¡¢Mubadala CapitalºÍMonograph Capital¡£¡£¡£Ollin Biosciences¾Û½¹¿ª·¢ÑÛ¿ÆÁ¢ÒìÒ©£¬£¬£¬£¬£¬£¬Á½¿î½¹µã¹ÜÏß»®·ÖΪÀ´×ÔÐÅ´ïÉúÎïµÄVEGF/Ang2Ë«¿¹IBI324£¬£¬£¬£¬£¬£¬³È·«Ò½Ò©µÄIGF-1R/TSHRË«¿¹VBS102¡£¡£¡£
1. 9ÔÂ17ÈÕ£¬£¬£¬£¬£¬£¬¼ÓÖÝ´óѧ¾É½ðɽ·ÖУµÄÑо¿Ö°Ô±ÔÚ¹ú¼Ê¶¥¼âѧÊõÆÚ¿¯ Nature ÉϽÒÏþÁËÌâΪ£ºCRISPR activation for SCN2A-related neurodevelopmental disorders µÄÑо¿ÂÛÎÄ¡£¡£¡£¸ÃÑо¿½« CRISPR ¼¤»î£¨CRISPRa£©¼¼ÊõÓ¦ÓÃÓÚ SCN2A µ¥±¶Ìåȱ·¦µÄÖÎÁÆ£¬£¬£¬£¬£¬£¬ÔÚÏ൱ÓÚÈËÀà 10 ËêµÄÇà´ºÆÚСÊóÄ£×ÓÖУ¬£¬£¬£¬£¬£¬Àֳɻָ´ÁËÆä´óÄÔÖÐ SCN2A ˮƽ£¬£¬£¬£¬£¬£¬Äæ×ªÁËÉñ¾·¢ÓýÕϰ¡£¡£¡£ÕâÅú×¢Îú×ÝÈ»´óÄԴ󲿷ÖÍòÓàÍê³ÉµÄÇéÐÎÏ£¬£¬£¬£¬£¬£¬SCN2A µ¥±¶Ìåȱ·¦ÈÔ¿É»ñµÃÓÐÓÃÖÎÁÆ¡£¡£¡£
[1]Tamura, S., Nelson, A.D., Spratt, P.W.E. et al. CRISPR activation for SCN2A-related neurodevelopmental disorders. Nature (2025). https://doi.org/10.1038/s41586-025-09522-w
Ïà¹ØÐÂÎÅ